NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

NCT03029273 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer, Nonsmall Cell, Recurrent

Interventions

DRUG: Cyclophosphamide and Fludarabine
BIOLOGICAL: Anti-NY-ESO-1 TCR transduced T cells

Sponsor

Guangzhou Institute of Respiratory Disease

Collaborators

[object Object]
[object Object]
[object Object]